Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
$9.6150
+0.1650 ( +6.60% ) 589.3K
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Market Data
Open
$9.6150
Previous close
$9.4500
Volume
589.3K
Market cap
$646.17M
Day range
$8.8210 - $9.9450
52 week range
$6.0650 - $19.7100
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q/a | Quarterly Reports | 59 | Jun 14, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
8-k | 8K-related | 13 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |